Research News and Research

RSS

West Pharmaceutical Services reports 13.3% increase in first-quarter consolidated sales

West Pharmaceutical Services, Inc. today announced its results for the first quarter of 2010.

30 Apr 2010

UC Irvine scientists receive CIRM grants for stem cell research

Two UC Irvine scientists will receive grants totaling more than $2.6 million to study the underlying biology of stem cells aimed at treating spinal cord injury, cancer and other disorders.

30 Apr 2010

SickKids receives $8.9M grant for autism research

A research team co-led by Dr. Stephen Scherer, Senior Scientist at The Hospital for Sick Children (SickKids) was awarded an $8.9 million grant today from the Global Leadership Round in Genomics & Life Sciences (GL(2)), which is part of the Ontario Research Fund (ORF) by the Ministry of Research and Innovation (MRI).

30 Apr 2010

IRIC launches new RNA engineering laboratory in Canada

The Institute for Research in Immunology and Cancer of the Universit- de Montr-al is proud to announce the launch of the very first ribonucleic acid engineering laboratory in Canada.

30 Apr 2010

WellTek reports 115% increase in gross profit for fiscal year 2009

WellTek Incorporated, a global health, fitness and wellness company, is pleased to announce that the Company reported $2.54 million in revenue for the 2009 fiscal year ended December 31, 2009, representing a 15% increase over $2.20 million in revenue posted for 2008. The increase is primarily attributable to international sales by the Company's subsidiary, MedX Limited.

30 Apr 2010

Clarient reports 14.8% increase in first quarter 2010 revenue

Clarient, Inc., a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the biopharmaceutical industry, today reported financial results for the first quarter ended March 31, 2010.

30 Apr 2010

Provenge cellular immunotherapy for men with advanced prostate cancer receives FDA approval

The U.S. Food and Drug Administration today approved Provenge (sipuleucel-T), a new therapy for certain men with advanced prostate cancer that uses their own immune system to fight the disease.

30 Apr 2010

The closing of St. Vincent's Hospital creates many uncertainties in N.Y.

The Wall Street Journal reports on the closing of St. Vincent's Hospital in Manhattan. One story details how the staff of St. Vincent's has not yet received details about the hospital's closing on Friday. The hospital has been slowly winding down services since it announced its closure. "The emergency room stopped admitting patients and ambulances started going elsewhere, leaving the emergency room focused on walk-ins. Their needs have run the gamut. Tuesday night, for example, brought a patient with a possible ruptured aorta...

30 Apr 2010

Study promises a new treatment for cancer

Cancer cells producing toxins that destroy tumours - could this be a future treatment for cancer? Researchers at Lund University have achieved good results in tests on both cells and animals.

30 Apr 2010

SCOLR Pharma first-quarter total revenues decrease 3%

SCOLR Pharma, Inc. today reported financial results for the first three months ended March 31, 2010.

30 Apr 2010

Depomed attributes 56% increase in first-quarter revenue to $5.8M increase in Glumetza product sales

Depomed, Inc. today reported financial results for the first quarter ended March 31, 2010.

30 Apr 2010

Study examines doctors' uncompensated daily work

The New York Times: "A new study detailing the uncompensated work burden on family doctors points to the need to change how they are paid, medical experts say — particularly as the new health care law promises to add millions more patients to the system. … Family doctors make up the embattled front line of the nation's health care system.

30 Apr 2010

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the first quarter of 2010.

30 Apr 2010

BioTime to acquire Singapore-based company, ES Cell International

BioTime, Inc., a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced that it has agreed to acquire the Singapore-based company ES Cell International Pte Ltd.

30 Apr 2010

Labopharm, Gruppo Angelini sign agreement to commercialize OLEPTRO in the U.S.

Labopharm Inc. and Gruppo Angelini today announced they have entered into an agreement to establish a joint venture in the United States for the commercialization of OLEPTRO, a novel once-daily formulation of the antidepressant trazodone approved by the U.S. Food and Drug Administration on February 3, 2010.

29 Apr 2010

Celgene's first-quarter non-GAAP total revenue up 31% to $789 million

Celgene Corporation announced non-GAAP net income of $294.6 million, or non-GAAP diluted earnings per share of $0.63 for the quarter ended March 31, 2010. Non-GAAP net income for the first quarter of 2009 was $205.1 million or non-GAAP diluted earnings per share of $0.44. Based on U.S. GAAP, Celgene reported net income of $234.4 million, or diluted earnings per share of $0.50 for the quarter ended March 31, 2010. GAAP net income for the first quarter of 2009 was $162.9 million, or diluted earnings per share of $0.35.

29 Apr 2010

Caliper Life Sciences' first-quarter 2010 GAAP revenues increase 1% to $28.7M

Caliper Life Sciences, Inc., today reported its first quarter 2010 results.

29 Apr 2010

Research initiative to study impact of microbes on human health, disease

The human species is dependent for its survival on the billions of microorganisms that inhabit multiple environmental niches within and on the human body. While microbes are commonly associated with diseases and infections, they are also vital in essential, beneficial roles such as digestion, where they help synthesize vitamins and ferment complex indigestible carbohydrates.

29 Apr 2010

Study investigates efficacy of acellular dermal matrix for intestinal elongation

Acellular dermal matrix (ADM) is a dermal biomaterial in which all of the cellular elements have been removed. The biologic properties of ADM, including its ability to support tissue regeneration repopulation with fibroblasts, revascularization, new collagen deposition and eventual absorption and replacement with native tissue permit its use in tissue reconstruction.

29 Apr 2010

First UK conference to address benefits of breastfeeding for babies with developmental disabilities

The first UK conference to address the benefits of breastfeeding for babies with developmental disabilities will be hosted by the University of Hertfordshire next week.

29 Apr 2010